touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial.
The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) (NCT02256436)’ (abstract number 4532) was presented at the 2021 ASCO Annual Meeting.
Questions
1. What were the 5-year findings of the study in terms of overall response rate and duration of response? (00:21- 02:45)
2. How did the safety profile of pembrolizumab compare with that of chemotherapy over 5 years? (02:45-03:17)
3. What has been the impact of this study on clinical practice? (03:17-04:15)
4. What are your thoughts on NICE’s withdrawn approval for pembrolizumab in patients with platinum-refractory advanced urothelial cancer? (04:15-05:29)
Disclosures: Dr Joaquim Bellmunt is the principle investigator of the KEYNOTE-045 trial and has received fees from Merck to be part of the advisory board.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the 2021 ASCO Annual Meeting.
